TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26681684
Drug: Sequential radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiotherapy with letrozole (arm B)
Study: 25194287
Drug: Strategy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy of adjusting therapy to achieve and maintain a target NT-proBNP level of <1,000 pg/ml
Study: 25194287
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (optimized guideline-recommended therapy)
Study: 22762346
Drug: DHEP-heparin plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP-heparin plaster
Study: 10362152
Drug: Methotrexate, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, 50 mg/m2
Study: 10362152
Drug: 6‐mercaptopurine, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mercaptopurine, 200 mg
Study: 30882641
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention involving nurses (reinforcing knowledge on antibiotics and UTI, decision aid diagram, communication skills improvement, increased involvement in prescription process).
Study: 26921746
Drug: Losartan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (12.5 mg twice per day for the 1st week, 25 mg twice per day during the 2nd week, and 75 mg/d from the 3rd week to the end of the 16th week)
Study: 23074234
Drug: Intensive i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive i.v. insulin therapy (BG = 70-110 mg/dl)
Study: 23074234
Drug: Standard s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard s.c. insulin therapy (BG = 70-180 mg/dl)
Study: 23074234
Drug: Intensive i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive i.v. insulin therapy
Study: 23074234
Drug: Standard s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard s.c. insulin therapy
Study: 15898439
Drug: Exchange of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exchange of cerebrospinal fluid and small dose of urokinase injection
Study: 12472706
Drug: Diclofenac suppositories
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppositories (approximately 1 mg x kg(‐1))
Study: 9824788
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral ganciclovir (6,000 mg/day)
Study: 9824788
Drug: Ganciclovir 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 2,000 mg every 8 hours alone
Study: 9824788
Drug: Ganciclovir 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 2,000 mg every 8 hours in combination with didanosine 200 mg every 12 hours
Study: 2732807
Drug: RRR‐alpha‐tocopherol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR‐alpha‐tocopherol 600 mg (900 IU) daily for 12 weeks
Study: 25652127
Drug: Monthly sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulphadoxine-pyrimethamine (SP)
Study: 25652127
Drug: Daily trimethoprim-sulphamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily trimethoprim-sulphamethoxazole (TS)
Study: 23623865
Drug: Vaccine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (two enteric-coated tablets consisting of no less than 4.5 log10 TCID50 of live ADV-4 or ADV-7)
Study: 19794312
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day), topiramate (25-150 mg/day)
Study: 19794312
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day)
Study: 16954722
Drug: Atazanavir/ritonavir (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (300/100 mg once daily)
Study: 16954722
Drug: Lopinavir/ritonavir (400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (400/100 mg twice daily)
Study: 2079570
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alfa‐2a at a dose of 4.5 million units thrice weekly for 4 months
Study: 492626
Drug: Propoxyphene (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene (64 mg)
Study: 31815370
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (control)
Study: 20148372
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg/kg
Study: 20148372
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg/kg
Study: 31488190
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg/kg (consumers)
Study: 31488190
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg/kg (non-consumers)
Study: 28291185
Drug: Surgical-site injection
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical-site injection containing ropivacaine, epinephrine, and morphine
Study: 28291185
Drug: Surgical-site injection
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical-site injection
Study: 24740134
Drug: AB103 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB103 high-dose (0.5 mg/kg)
Study: 24740134
Drug: AB103 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AB103 low-dose (0.25 mg/kg)
Study: 24740134
Drug: AB103 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB103 high-dose
Study: 24740134
Drug: AB103 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AB103 low-dose
Study: 24740134
Drug: AB103 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB103 (both doses)
Study: 22995588
Drug: Two-Dimensional Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-Dimensional Conventional Radiation Therapy (2D‐CRT)
Study: 18085144
Drug: Ear point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear point taping and pressing therapy
Study: 18085144
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Indomeixin enteric tablets)
Study: 15129731
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (4 g daily)
Study: 1524161
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg daily
Study: 6337425
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1000 mg daily
Study: 31216027
Drug: High-dose PNE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PNE (N=20)
Study: 31216027
Drug: Low-concentrated dose
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentrated dose PNE (N=20)
Study: 31216027
Drug: Diluted low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diluted low-dose PNE (N=20)
Study: 31216027
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (N=17)
Study: 30641350
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.1, 0.2, 0.5, and 1.0 mg/kg)
Study: 30641350
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (intravenous midazolam)
Study: 26561332
Drug: RAISE protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAISE protocol (Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease)
Study: 26561332
Drug: Conventional Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Intravenous immunoglobulin (IVIG) protocol
Study: 26561332
Drug: Positive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive group (patients with positive anti-YPT and/or anti-YPM antibodies)
Study: 26561332
Drug: Negative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative group (patients without positive anti-YPT and/or anti-YPM antibodies)
Study: 19835116
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Fluoxetine Hydrochloride at 20 mg daily
Study: 15063441
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (intravenous)
Study: 25966132
Drug: Concurrent radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent radiochemotherapy
Study: 23386053
Drug: 0.3% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ropivacaine infusion at 4 mL/h for 64 hours
Study: 23386053
Drug: 0.3% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ropivacaine infusion
Study: 21574787
Drug: Q500 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q500 (500 mg quercetin·day(‐1))
Study: 21574787
Drug: Q1000 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q1000 (1000 mg quercetin·day(‐1))
Study: 15569112
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg intravenously
Study: 17272998
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg intravenously as infusion
Study: 17272998
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg intravenously as bolus injection
Study: 15585685
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a daily dose of 33 microg/kg (0.1 U/kg)
Study: 15585685
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for >2 years before puberty
Study: 15585685
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for <2 years before puberty
Study: 842813
Drug: Naloxone 0.1-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.1-0.2 mg i.v.
Study: 842813
Drug: Naloxone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.2 mg i.m. (if required)
Study: 24604835
Drug: Outpatient intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient intravenous cefepime 50 mg/kg (12 hourly)
Study: 24604835
Drug: Inpatient intravenous
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient intravenous cefepime 50 mg/kg (12 hourly)
Study: 22411278
Drug: Modified Melodic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Melodic Intonation Therapy (MMIT)
Study: 15632666
Drug: Low progestin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low progestin oral contraceptives
Study: 15632666
Drug: High progestin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High progestin oral contraceptives
Study: 15632666
Drug: Active pill
Normalized name: Factive Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pill phase
Study: 15632666
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill phase
Study: 1329479
Drug: Lisinopril 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5‐20 mg once daily
Study: 1329479
Drug: Digoxin 0.125‐0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.125‐0.375 mg once daily
Study: 28854500
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity laser therapy (HILT) combined with spinal decompression system (SDS)
Study: 26862829
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg RBP-7000
Study: 26862829
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg RBP-7000
Study: 24829213
Drug: Measles vaccination
Normalized name: Measles vaccine (live)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccination (MV) in the presence of maternal antibody
Study: 24829213
Drug: Measles vaccination
Normalized name: Measles vaccine (live)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccination (MV) without maternal antibody
Study: 24829213
Drug: Combined analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined analysis of measles vaccination (MV) with maternal antibody
Study: 16263359
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (IRT) using tungsten (188W) at doses of 18, 22, or 25 Gy
Study: 16263359
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (IRT) using tungsten (188W)
Study: 23108415
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.5 µg/kg/h)
Study: 30109908
Drug: B-GOS® (2.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-GOS® (2.75 g/d)
Study: 27001136
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy according to the Utrecht School (MTU)
Study: 10833739
Drug: Fluoxetine (Prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Prozac) with information about weight loss side effects
Study: 10833739
Drug: Fluoxetine (Prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Prozac) without information about weight-related side effects
Study: 8335047
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 gram dose of ceftazidime with the induction of anaesthesia
Study: 8335047
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g daily ceftazidime from induction of anaesthesia until removal of the urethral catheter (but ≤ 5 days)
Study: 8335047
Drug: Ceftazidime-treated groups
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime-treated groups (both single-dose and multidose)
Study: 3567048
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion at rates of 6.1 mg min‐1 and above
Study: 3567048
Drug: Inosine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine infusion at dose rates up to 16.8 mg min‐1
Study: 17167135
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine
Study: 21979801
Drug: Sitaxsentan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan (100 mg/day)
Study: 15051614
Drug: DHA (4.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (4.9 g/d)
Study: 15051614
Drug: EPA (4.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (4.7 g/d)
Study: 9772929
Drug: Anti Gp
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti Gp IIb‐IIIa (Reopro chimeric antibody, Abciximab®)
Study: 16060203
Drug: Homeopathic medicine
Normalized name: Homeopathic medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicine
Study: 2905500
Drug: Lormetazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.03 mg/kg IV) + ZK 93 426 (0.04 mg/kg IV)
Study: 2905500
Drug: Lormetazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.03 mg/kg IV)
Study: 2905500
Drug: ZK 93
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 93 426 (0.04 mg/kg IV)
Study: 26372539
Drug: ICD‐9‐CM code
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD‐9‐CM code for dermatitis due to drug (693.0)
Study: 26372539
Drug: ICD‐9‐CM code
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD‐9‐CM code for adverse reaction to drug (995.2)
Study: 26372539
Drug: ICD‐9‐CM code
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD‐9‐CM code and E code combination
Study: 26372539
Drug: Overall allergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall allergic drug reactions
Study: 26372539
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of allergic drug reactions
Study: 23283449
Drug: Uniform multidrug
Normalized name: Eugenia uniflora whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniform multidrug therapy (U‐MDT) for leprosy
Study: 23283449
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment regimen for leprosy
Study: 17668537
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir suppressive therapy (1 g once daily for 6 months)
Study: 17668537
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir episodic therapy (two 2-g doses separated by 12 hours at first sign of prodrome for 6 months)
Study: 16265352
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with chemotherapy (weekly 5-fluorouracil and leucovorin 500 and 20 mg m(‐2), respectively)
Study: 16265352
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with chemotherapy (daily x 5 Mayo Clinic schedule 425 and 20 mg m(‐2), respectively)
Study: 16265352
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with chemotherapy (Mayo schedule)
Study: 16265352
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (at onset of predefined symptoms)
Study: 16265352
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with chemotherapy
Study: 31002483
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment
Study: 23888450
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) ointment
Study: 8672820
Drug: 20% lipid
Normalized name: Smoflipid 20% Lipid Emulsion for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% lipid emulsion amphotericin B (1 mg/mL)
Study: 8672820
Drug: Conventional amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional amphotericin B (0.1 mg/mL) in dextrose 5% solution
Study: 31833259
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) without interval debulking surgery
Study: 22011907
Drug: briakinumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: briakinumab (200 mg at weeks 0 and 4 and 100 mg at week 8)
Study: 22011907
Drug: briakinumab 100
Normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: briakinumab 100 mg every 4 weeks (q4-wk)
Study: 22011907
Drug: briakinumab 100
Normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: briakinumab 100 mg every 12 weeks (q12-wk)
Study: 12481893
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate vaccine
Study: 11210884
Drug: Parenteral piperacillin/tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral piperacillin/tazobactam (3.375 g every 6 hours for 48 h)
Study: 11210884
Drug: Parenteral piperacillin/tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral piperacillin/tazobactam plus topical piperacillin/tazobactam administered as a mouthwash immediately before surgery and once a day for 2 days postoperatively
Study: 19015485
Drug: MK-677 25
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 25 mg
Study: 7948820
Drug: IFN-alpha-2a therapy
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha-2a therapy
Study: 3283625
Drug: Low-dose IFN
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFN alpha-2c (1.2 x 10 IU/m x 28 days s.c. or lower)
Study: 3283625
Drug: Daily IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IFN
Study: 30188590
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL sucrose (25% in South Africa, 24% in Norway)
Study: 30188590
Drug: 0.2 mL
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL sucrose (25% in South Africa, 24% in Norway)
Study: 30188590
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL sucrose
Study: 30188590
Drug: 0.2 mL
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL sucrose
Study: 23228922
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (BB)
Study: 23228922
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (BB) in high-risk patients (GRACE risk scores ≥121)
Study: 23228922
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (BB) in high-risk patients (administered diuretics)